InMed to Present at the Emerging Growth Conference
InMed to Present at the Emerging Growth Conference
Vancouver, British Columbia–(Newsfile Corp. – June 10, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024.
不列顛哥倫比亞省溫哥華-(Newsfile Corp.-2024年6月10日)-InMed Pharmaceuticals Inc.(納斯達克:INM)(下稱"InMed"或"公司"),一家專注於開發一系列專利小分子藥物候選藥物的臨床階段藥品公司，今天宣佈公司將在即將舉行的2024年6月12日至13日的新興增長會議上發表演講。
InMed's CEO, Mr. Eric A. Adams, will present a corporate overview followed by a questions and answers session. Presentation details are as follows:
InMed的首席執行官Eric A. Adams先生將介紹公司的概況，之後進行問答環節。演講細節如下：
InMed's presentation at Emerging Growth Conference 72:
Date: June 13, 2024
Time: 1:45pm EDT
Registration: https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=eg
InMed在Emerging Growth Conference 72上的介紹：
日期：2024年6月13日
時間：東部夏令時下午1:45
註冊： https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=eg
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com, Emerging Growth YouTube Channel or InMed's investor relations events page.
如果參與者無法在會議當天實時參加活動，則存檔的網絡廣播也將可供使用。 EmergingGrowth.com, 新興成長YouTube頻道或。InMed的投資者關係活動頁面.
About InMed:
關於InMed：
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. For more information, visit www.inmedpharma.com.
InMed Pharmaceuticals是一家臨床階段製藥公司，專注於開發臨床前小分子藥物候選藥物，針對CB1/CB2受體。InMed的業務涵蓋阿爾茨海默病、眼科和皮膚病治療領域的三個項目。與其子公司BayMedica一起，我們是稀有大麻素和專有大麻素類似物的製造、開發和商業化的全球領導者。欲知更多信息，請訪問www.inmedpharma.com.
About the Emerging Growth Conference
關於新興成長會議
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
Emerging Growth conference是上市公司以便捷方式向投資社區展示和傳達其新產品、服務和其他重大公告的有效方式。
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
此次會議的重點和覆蓋範圍包括許多增長部門的公司，這些公司都有強大的管理團隊、創新性的產品和服務、專注的策略、執行力以及長期增長的整體潛力。受衆包括潛在的數萬名個人和機構投資者，以及投資顧問和分析師。
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: [email protected]
投資者聯繫人：
Colin Clancy
投資者關係副總裁
和企業通訊
電話：+1.604.416.0999
電子郵件: [email protected]
Cautionary Note Regarding Forward-Looking Information:
有關前瞻性信息的警示：
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
本新聞稿包含"前瞻性信息"和"前瞻性陳述"（統稱爲"前瞻性信息"）, 根據適用的證券法規定義。前瞻性陳述經常使用"預計"、"期望"、"認爲"、"打算"、"潛在"、"可能"、"將"或類似表達方式進行標識。這些陳述基於管理層當前的期望，圍繞着許多風險、不確定和假設展開，其中很多超出了我們的掌控能力。前瞻性信息是基於管理層當前的預期和信仰，並且會受到一系列風險和不確定因素的影響，這些風險和不確定因素可能會導致實際結果與前瞻性陳述中描述的結果有所不同。
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
此外，還存在已知和未知的風險因素，可能導致InMed的實際結果、表現或業績與本文中所包含的前瞻性信息所表達的任何未來結果、表現或業績有實質性的不同。InMed及其獨立業務所面臨的風險和不確定性的全面討論在InMed的年度報告(表格10-K)和提交給證券交易委員會的其他文件中已披露。www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
此處所有的前瞻性信息都受到這一警示聲明的限制，並且InMed放棄了對任何此類前瞻性信息進行修訂和更新或公開宣佈任何對此類前瞻性信息所做修訂的結果來反映未來的結果、事件或發展的義務，除非法律要求其這樣做。
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/212397
要查看此新聞發佈的源版本，請訪問 https://www.newsfilecorp.com/release/212397
譯文內容由第三人軟體翻譯。